NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform

ENvue Medical, Inc.

ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.
U.S. enteral-feeding devices market projected at ~$1.8B by 2030; ENvue is 510(k)-cleared for adults.
Company planning name change to ENvue Medical and new NASDAQ ticker symbol.
Exploring strategic alternatives (partnerships/divestitures) for legacy PainShield and UroShield technologies.
CEO Doron Besser (appointed June 2025) outlines multi-phase roadmap including pediatric, imaging, and vascular applications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.